This presentation will showcase Real-World Evidence gathered with patients who have received MDMA-assisted therapy for PTSD as permitted under the Therapeutic Goods Administration’s legal framework since October 2023. Our service has been evaluating MDMA-assisted therapy’s impact on PTSD and broader trends on symptoms, quality of life, and substance use patterns. Using validated assessments, we observed substantial improvements in patient well-being and functional health, with early indications that MDMA-assisted therapy may benefit additional mental health conditions beyond PTSD. We’ll discuss the potential of MDMA-assisted therapy to help with other indications, the challenges of regulatory compliance, and key insights on patient safety. Our findings underscore the need for further research to explore the wider applications of MDMA-assisted therapy and its capacity to impact mental health care.